Anorexia
-
Subject Areas on Research
- A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
- A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
- Acute toxicity of proton beam radiation for pediatric central nervous system malignancies.
- Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
- Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes.
- Cachexia and aging: an update based on the Fourth International Cachexia Meeting.
- Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
- Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.
- Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36.
- Efficacy of felbamate in therapy for partial epilepsy in children.
- Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII.
- Management of terminal cancer in elderly patients.
- Mifepristone (RU 486) for Alzheimer's disease.
- Multisite studies offer a solution to recruitment challenges in palliative care studies.
- Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
- Overcoming obstacles in the design of cancer anorexia/weight loss trials.
- Pathophysiology and treatment options for cardiac anorexia.
- Peptide YY: a gut hormone associated with anorexia during infectious diarrhea in children.
- Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
- Phase I trial of pazopanib in patients with advanced cancer.
- Phase II study of docetaxel in advanced soft tissue sarcomas.
- Pituitary abnormalities in eating disorders: further evidence from MRI studies.
- Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
- Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.
- Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.
- Reversal of diet-induced obesity increases insulin transport into cerebrospinal fluid and restores sensitivity to the anorexic action of central insulin in male rats.
- Symptom Burden and Performance Status among Community-Dwelling Patients with Serious Illness.
- The anorectic effect of GLP-1 in rats is nutrient dependent.
- The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.
- The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice.
- Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).
- Virtual reality as a distraction intervention for women receiving chemotherapy.
- What are the criteria for response to cachexia treatment?